The role of pharmacology in spinal cord protection during thoracic aortic reconstruction.
Surgery of the thoracic aorta continues to have a significant risk of neurologic complication. Several strategies to minimize this risk are emerging. Pharmacologic protection from these complications continues to be researched, but at this point few medications are being used clinically. This article reviews the pathophysiology of ischemic spinal cord injury and summarizes the investigational pharmacology that may prevent these serious complications.
Reece
T Brett
TB
Department of Surgery, Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA 22908, USA.
Kern
John A
JA
Tribble
Curtis G
CG
Cassada
David C
DC
D058917:Adenosine A2 Receptor Antagonists; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001013:Aorta, Thoracic / Q000473:pathology / Q000601:surgery*; D017544:Aortic Aneurysm, Abdominal / Q000601:surgery; D017545:Aortic Aneurysm, Thoracic / Q000601:surgery; D006801:Humans; D007430:Intraoperative Care; D007431:Intraoperative Complications / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D043705:Receptor, Adenosine A2A / Q000627:therapeutic use*; D013119:Spinal Cord Injuries / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D020760:Spinal Cord Ischemia / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D019616:Thoracic Surgical Procedures
D058917:Adenosine A2 Receptor Antagonists; D000893:Anti-Inflammatory Agents; D043705:Receptor, Adenosine A2A